Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-925 in Moderate to Severe Dry Eye Disease
NCT06225973Phase 2Active, not recruiting
- Sponsor
- Telios Pharma
- Start
- Feb 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TL-925 in dry eye disease (DED), sponsored by Telios Pharma. Started Feb 2024; status: active, not recruiting.
02
Drugs
TL-925
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06225973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225973.